Jen Herbach

Jen Herbach, Founder and CEO of Adventris Pharmaceuticals, is on a mission to revolutionize cancer treatment with innovative vaccines targeting the KRAS mutation. She shares how her experience at Y Combinator reshaped her approach, emphasizing hands-on leadership and accountability in her team. Jen outlines the exciting potential of cancer vaccines for prevention, particularly in localized pancreatic cancer. She also reveals the delicate balance of investor relations and decision-making power that has shaped Adventris's journey.